ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms:

* Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains) or Streptococcus pneumoniae (including multidrug-resistant strains [MDRSP*])

ZYVOX in the treatment of NP/VAP
* Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers

ZYVOX in the treatment of cSSSI
ZYVOX in the treatment of DFI
* Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes
* Vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia
* Community-acquired pneumonia caused by Streptococcus pneumoniae (including multidrug-resistant strains [MDRSP*]), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only)

* MDRSP refers to isolates resistant to 2 or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole.